Will new capsule launch in US boost Lupin?

| Updated on October 04, 2019 Published on October 04, 2019

Lupin has launched Mycophenolate Mofetil Capsules USP, 250 mg in the US. Lupin’s alliance partner Concord Biotech had received approval from the USFDA earlier.

These capsules are an anti-metabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants and should be used in combination with other immunosuppressants. Mycophenolate Mofetil Capsules had annual sales of about $53 million in the US.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on October 04, 2019
This article is closed for comments.
Please Email the Editor